GlassScriptPhysician profile
Lori Bartran Howell
NPI 1366999799
$9,617.84
in general payments reported to CMS, 2019-2025
26 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,886 · 2022: $1,934 · 2023: $1,777 · 2024: $1,862 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,410 · Education: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,409.74 |
| Education | $388.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,249.60 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,880.58 | 2021-2025 | |
| Janssen Biotech, INC. | $713.15 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $696.88 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $625.48 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $557.34 | 2021-2025 | |
| Leo Pharma INC. | $434.28 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $416.55 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $335.06 | 2021-2024 | Arazlo, Cabtreo, Jublia |
| Regeneron Healthcare Solutions, INC. | $281.81 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $219.87 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $179.85 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $158.37 | 2021-2025 | Blu-U |
| Pfizer INC. | $141.11 | 2021-2024 | |
| Incyte Corporation | $116.18 | 2021-2024 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $113.34 | 2023-2025 | Puraply, Apligraf |
| Sanofi-Aventis U.S. LLC | $89.95 | 2023 | |
| Almirall LLC | $87.12 | 2021-2023 | Seysara |
| Dermavant Sciences, INC. | $83.73 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $77.22 | 2023-2025 | Zoryve |
| Sandoz INC. | $44.64 | 2024 | Hyrimoz |
| Genentech USA, INC. | $36.31 | 2021-2024 | Xolair |
| Nevro Corp. | $24.22 | 2024 | Senza |
| Mayne Pharma Commercial LLC | $20.51 | 2021 | |
| Fresenius Kabi USA, LLC | $19.62 | 2023 | Idacio |
| Botanix Sb INC | $15.07 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.